1.Diagnosis and treatment analysis of 5 cases with retroperitoneal neuroendocrine carcinoma
Cancer Research and Clinic 2012;24(9):607-609
Objective To analyze the clinical features and diagnostic experiences of retroperitoneal neuroendocrine carcinoma (NEC).Methods Clinical data of primary retroperitoneal NEC from January 2000 to January 2012 were retrospectively collected and analyzed.Results Five candidates were included 4 male and 1 female.The median age was 53 years old.3 cases initially suffered from abdominal pain and radiative back pain,2 cases were confirmed by normal physical check.The CT scan and B type ultrasound were performed among all patients,1 case was diagnosed as pancreas head neoplasm,1 case pancreas insulinoma,which was closely associated with other tissues and the intervational therapy was performed twice preoperatively.All 5 cases were selected surgery as the main treatment,2 cases performed radical tumor resection,3 cases received bypass operation.2 cases were 3 years survival.Conclusion Retroperitoneal NEC is a rare carcinoma,characterized by seriously invasion and high malignant degree.Surgery still remains the mainstay of selections,early diagnosis can significantly improve NEC patients’ overall survival rate.But the early diagnosis rate of this rare kind of patients still need to be improved.
2.Clinical observation of endoscopic submucosal dissection in treating wide base colonic polyps comparing with laparoscopic surgery
Baoying HU ; Haihua ZHOU ; Shuai YUAN
China Journal of Endoscopy 2017;23(3):9-13
Objective To evaluate the clinical effects and complications in treating colonic polyps between endoscopic submucosal dissection and laparoscopy.Methods 69 colonic polyps patients diagnosed by colonoscopy with the basal body diameter of the colonic polyp >2.0 cm were enrolled in this study. All the patients were divided into study group (n = 41) and control group (n = 28) according to patients' decision, and then treated with ESD and laparoscopic surgery separately. After treatment, all the patients were followed up and repeated colonoscopy after 6 months. Clinical data were recorded and analyzed at the end of the research.Results Patients were successfully operated in both groups. 1 case in each group was diagnosed of malignant tumor and needed further treatment. The average operation time in study group and the control group was (85.00± 36.50) min and (110.00 ± 45.70) min (P < 0.05), length of hospital stay of the two groups were (10.69 ± 3.09) d and (11.61 ± 6.41) d (P < 0.05), and average cost of hospitalization of the two groups were (15.7 ± 2.7) ten thousand RMB and (30.6 ± 5.9) ten thousand RMB (P < 0.05). Percentage of complications in the study group was 2.43% comparing to 14.29% of control group(P < 0.05). 1 case in the study group complicated with enteron hemorrhage. Complications in the control group was 2 cases of ileus, 1 case of infection, 1 case of intestinal fistula. No recurrence was found in the two groups after 6 months in the repeat colonoscopy.Conclusion Both of the two treatments are effective for patients with wide base colonic polyps, but malignant tumor must be cautioned when treating with wide base colonic polyps. Endoscopic submucosal dissection requires proficient skill while with less impairment and cost.
3.Progress in the treatment of central serous chorioretinopathy
Yuan-Lu, SHUAI ; Wang-Yi, FANG ; Song-Tao, YUAN
International Eye Science 2016;16(11):2059-2062
Central serous chorioretinopathy( CSC) is an important cause for central vision loss. It mostly occurs in young and middle-aged men. It is a condition characterized by a serous detachment of neurosensory retina at the posterior pole and leakage from the retinal pigment epithelium ( RPE ) . Most patients with acute CSC will resolve spontaneously. However, in cases of chronic CSC with persistent serous retinal detachment, patients might develop progressive vision loss. This article was made a brief review of the current treatment methods, including laser, photodynamic therapy ( PDT ) , intravitreal anti-vascular endothelial growth factor therapy and the mineralocorticoid receptor antagonists.
4.Determination of Tectoridin in Rhizoma Iridis Tectori by HPLC
Jia WANG ; Chongjun YUAN ; Yuguang YOU ; Shuai CHENG
China Pharmacy 1991;0(06):-
OBJECTIVE:To determine the content of Tectoridin in Rhizoma Iridis Tectori by HPLC. METHODS: The chromatographic separation was performed on Diamond ODS C18 column(150 mm?4.6 mm,5 ?m) with mobile phase consisted of MeOH-0.5% acetic acid(3∶7) at a flow rate of 0.8 mL?min-1. The detection wavelength was set at 265 nm.RESULTS: Good linear relationship was achieved over the concentration range of 0.079 2~0.396 0 ?g for tectoridin with an average recovery of 99.80%(RSD=1.09%,n=6). CONCLUSION: The method is sensitive, simple and accurate, and it can be used for the quality control of Rhizoma Iridis Tectori.
5.Quality Control of Preanalytical Variations for the Determination of Trace Element Aluminum, Arsenic,Chromium, Cadmium and Mercury in Samples of Human Origin
Kun ZHONG ; Wei WANG ; Falin HE ; Shuai YUAN ; Zhiguo WANG
Journal of Modern Laboratory Medicine 2017;32(2):160-164
The aims of this article is to provide the quality control requirements of preanalytical variation for the determination of trace element aluminum,arsenic,chromium,cadmium and mercury in samples of human origin,reduce the influence of preanalytical variation on the test results.Refer to the Clinical and Laboratory Standards Institute (CLSI) documents,Control of Preanalytical Variation in Trace Element Determinations and other references and guidelines,the methods of quality control of aluminum,arsenic,chromium,cadmium and mercury determination have been made,including:the factors needed to be considered in collection,preservation,transportation and other preanalytical factors,the abilities and considerations of laboratory staff,etc.Hope this article provide some useful suggestions and help to the laboratories of determination of aluminum,arsenic,chromium,cadmium and mercury in samples of human origin.
6.Preparation of compound tissue-engineering scaffolds of PLA/silk fibroin and evaluation of its biological features
Shuai XING ; Yayi XIA ; Lingwei YUAN ; Maoshen LU
Journal of Jilin University(Medicine Edition) 2006;0(03):-
Objective To study the preparation method of compound tissue-engineering scaffolds of the PLA/silk fibroin and evaluate its biological features.Methods The PLA scaffolds matrix were dipped into the silk fibroin solution,then dried,and PLA/silk fibroin scaffolds were prepared.There were two groups in the experiment,one group was PLA group,and the other one was compound scaffolds group.According to ISO-10993 standard,hematolysis test,dynamic coagulation time test,cell toxicity test,stimulation test and pyrogen test were performed in two groups,and the results were compared betwen two groups.Results In the stimulation test,the two kinds of materials had equally not aroused the obvious animal skin stimulation,it showed that the experiment was in accordance with the standard.In the pyrogen test,the two scaffolds material aroused the animal temperature rising without exception under 0.2℃ and the total number of degree was under 1.0℃,therefore there was no obvious difference between two groups.In the hematolysis test,the hemolysis rates of the two scaffolds samples were smaller than 5% equally(P=0.000),which indicated that the hemolysis of the compound scaffolds was better than that of the PLA scaffolds.In the dynamic coagulation time test,the coagulation time of the compound scaffolds(37 min) was longer than that of the PLA scaffolds(26 min).The anti-coagulation ability of the compound scaffolds was better than that of the PLA scaffdds.In the cell toxicity test,the cell growth situation of the compound scaffolds group was obviously better than that of the PLA group,and at the meantime the cell toxicity of the compound scaffolds was obviously smaller than that of the PLA scaffolds.Conclusion The material of PLA/silk fibroin compound scaffolds has the advanced biological consistent compared with the simplex scaffolds.Accordingly,the PLA/silk fibroin can be used as a scaffolds matrix to be transplanted into the body.
7.Survey and Analysis for Maternal Serum Marker of Prenatal Screening in Second Trimester in 2 0 1 5
Falin HE ; Wei WANG ; Kun ZHONG ; Shuai YUAN ; Zhiguo WANG
Journal of Modern Laboratory Medicine 2017;32(1):154-156,164
Objective To investigate the dates of 477 Chinese prenatal screening centers for previous half year analyse prena-tal screening status and provide recommendations for quality control.Methods All China prenatal screening centers were sent the data via the National Quality Assessment Scheme.This covered the software used,the risk cut-offs,monthly sample throughput,monthly median MoM of AFP,hCG,β-HCG,freeβ-HCG and uE3,monthly screening positive rate for trisomy 21,trisomy 18 and Open Neural Tube Defect.Results Screening protocol were versatile,with 73.48% (133/181)used two-marker model,24.31% (44/181)used three-marker model and 2.21% used four-marker model.About the software used, 350 laboratories never updated the screening parameters,89 laboratories had updated their median or parameter by manufac-turers,24 laboratories had updated the parameters by themselves.Cut-offs differed between laboratories.59.91% (275/459) used 1/270 as their cutoffs for trisomy 21.66.22% (296/447)used 1/350 as their cutoff for trisomy 18 and 96.52% (361/374)used cutoffs between 2.0~2.5 MOM for ONTD.Results of monthly median MOM:the percentage of laboratories that all six monthly median MOM within the target of 0.90~1.10 was 46.69% (155/332)for AFP,20.0% (4/20)for hCG, 29.17% (28/96)forβ-HCG,15.66% (31/198)for freeβ-HCG and 4.82% (11/228)for uE3.The percentage of laborato-ries that all six monthly median MOM within the target of 0.95~1.05 was 14.16% (47/332)for AFP,0% (0/20)for hCG,4.17% (4/96)forβ-HCG,12.63% (25/198)for freeβ-HCG and 4.82% (11/228)for uE3.About screening positive rate,there were difference of trisomy 2 1 positive rate in the same laboratory within the six month.Conclusion There were variations types of screening protocol,different kinds of soft platform,randomness of choice or update of medians or other important parameters and great difference in awareness of quality control.It would be taken effective and practical quality control measures to help laboratories improve quality control.
8.The diagnosis, treatment and prognosis of colorectal small cell carcinoma: an analysis of 15 cases
Shuai HUANG ; Zhaoxu ZHENG ; Quan XU ; Xinghua YUAN
Chinese Journal of General Surgery 2013;28(12):961-964
Objective To summarize and analyze the clinical feature,therapeutic mnethods and prognosis of colorectal small cell carcinoma.Methods From January 2000 to January 2012,15 patients of colorectal small cell carcinoma were analyzed retrospectively.Results There were 12 male cases,3 females.The age at diagnosis was between 39-71 years,with median age of 60.SCC located in the rectum in 12 cases,in the colon in 3 cases.The time from the onset of symptoms to final diagnosis was from 1 to 12 months.The diameter of tumors varied from 2.5 to 8.0 cm.13 cases received up-front surgery,including radical tumor resection in 6 cases,palliative resection in 7 cases,and neoadjuvant-chemotherapy followed by palliative resection in one case.The initial Ⅰ,Ⅲ B,Ⅳ B stage were 1 case,6 cases and 8 cases,respectively.The overall median survival time is 11 months,1,2 year's survival rate is 40.0% and 20.0%,respectively.Conclusions Colorectal SCC is less common and the prognosis is poor.Multimodality management,with radical surgical resection of the primary lesion followed by standard adjuvantchemotherapy,affords good local disease control and a fair survival.
9.Gallbladder small cell carcinoma: report of five cases and review of literature
Shuai HUANG ; Zhaoxu ZHENG ; Quan XU ; Xinghua YUAN
Chinese Journal of General Surgery 2013;28(7):489-491
Objective To study the clinical features of gallbladder small cell carcinoma (GSCC),to improve the diagnosis and treatment of GSCC.Methods We retrospectively analyzed the clinical data of GSCC patients at our hospital from January 2000 to January 2012,and made a collective review of the literature.Results In this series,there were four female cases,one male case,the age at the first diagnosis was between 42-67,with the median age of 57.The main complain was pain and dis-comfort on the up and right abdomen.Tumor located in the bottom of gallbladder in 3 cases,and in the body in 2.Cholelithiasis was complicated in 4 cases.2 patients received radical resection of GSCC,followed by adjuvant chemotherapy of VP-16 and cisplatin,radioactive therapy in one.Postoperatively,these two were followed up for 45 and 32 mons with tumor free survival.3 cases received palliative resection,followed by adjuvant chemoradioactive therapy or intervention treatment,these three were followed up to 8,11,30 months respectively to their death for tumor recurrence.Conclusions GSCC is a rare disease,the initial symptoms are not often specific and easily misdiagnosed.The prognosis of GSCC is poor.
10.Study on the Quality Standard of Belamcandin Standard Substance
Chongjun YUAN ; Jia WANG ; Shuai CHEN ; Sen LUO ; Xuemin XU
China Pharmacy 2007;0(33):-
OBJECTIVE:To establish the quality standard of Belamcandin standard substance.METHODS:Different indices of standard Belamcandin were examined with quantitative and quantitative analyses according to the corresponding measures stipulated in the Appendix of pharmacopoeia of people's republic of China(part Ⅱ)published in 2005.RESULTS:The specific rotatory power of 3 batches of standard Belamcandin was —28?~—30?([?]25 D,c0.11,Pyridine);the E1% 1 cmwas 790~830;the melting point was 252~254 ℃ and the ash content was less than 0.5%.The content of Belamcandin in the products was above 99.5% as revealed by HPLC.CONCLUSION:All of the indices were shown to meet the standards for standard substances and the established standard can be used for the quality control of standard Belamcandin.